Pixelworks, Inc. ( NASDAQ: PXLW) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Brett Perry - Shelton Group, Investor Relations Todd DeBonis - President and Chief Executive Officer Haley ...

CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene ...

Binding term sheet grants Modulant Biosciences exclusive global rights to develop and commercialize EL-22 for animal health, enabling a ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients ...

Company executed a settlement agreement with GEM Group. Under terms of the settlement agreement, GEM has a 55-day due diligence period, subject to extension by GEM, to evaluate the transfer ...

Multi-year collaboration will deploy up to 500 megawatts of AI infrastructure, powered by the full spectrum of AMD compute ...

Why India’s foreign policy and India’s Military Doctrine is relevant to the UPSC exam? What is the significance of topics ...

Peter Sullivan has maintained his innocence since he was given a life sentence in 1987 for the murder of Diane Sindall ...

Under the terms of the agreement, Renovaro and Amsterdam UMC will work together to refine and improve predictive performance, ...

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., ...

Binding term sheet grants Modulant Biosciences exclusive global rights to develop and commercialize EL-22 for animal health, enabling a first-of-its-kind probiotic approach to muscle preservation in ...

Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system disorders, today announced that it has entered into a $570 million term loan and ...